Premenopausal women with major depressive disorder (MDD) have less bone mineral density (BMD) than those without MDD, according to findings of a study published in the November 26 issue of Archives of Internal Medicine. Researchers reported that the level of bone loss in premenopausal women with MDD was at least as high as that associated with recognized risk factors for osteoporosis. The study was funded by the National Institute of Mental Health, the National Institute of Diabetes and Digestive and Kidney Diseases, the National Center for Complementary and Alternative Medicine, and the Warren Magnuson Clinical Center of the NIH.
Drug Benefit Trends
Although the hospitalist model is rapidly altering inpatient care—an estimated 29% of American hospitals have hospitalists on staff and more than 12,000 hospitalists practice in the United States—little information about the clinical and economic outcomes of care by hospitalists is available.
In the November issue of Drug Benefit Trends, a Viewpoint titled "How Can We Improve Drug Safety?" and an Editorial titled, "Is the Time Right for a BTC Drug Class?" seemed to send mixed signals about whether there should be a third category of medications stocked behind the counter (BTC) for which pharmacists would provide counseling.
Oral Contraceptives: Five Vignettes Illustrate Dx and Rx Problems-- and Solutions
Phenytoin is one of the most commonly prescribed antiepileptic drugs in both acute and chronic settings; its use has been extensively described. Nevertheless, interactions between phenytoin and numerous other drugs continue to complicate seizure therapy; these have been documented in case reports, studies, textbooks, and epilepsy reviews.
The potential for ocular side effects in patients taking selective phosphodiesterase (PDE) 5 inhibitors has been documented.
Elderly patients who take many medications often have difficulty in remembering them all.
recently became available for the
treatment of high LDL cholesterol
levels, as adjunctive therapy to dietary
modification, in patients with
primary hypercholesterolemia or
mixed hyperlipidemia. This drug,
from Merck/Schering-Plough Pharmaceuticals,
inhibits the production
of cholesterol in the liver and blocks
the absorption of cholesterol in the
GI tract, including cholesterol obtained
Nitazoxanide (Alinia), from Romark
Laboratories, has been approved
by the FDA for the treatment of
children who have diarrhea caused
by protozoa. This agent targets
Cryptosporidium parvum and
Pitfalls in Prescribing: Macrolide-Drug Interactions: Update on the Most Common and Clinically Significant
Macrolides are commonly
used to treat a
variety of infections.
long been recognized
as having numerous highly important
drug interactions.1 Although
clarithromycin generally has somewhat
less of an effect on the clearance
of other drugs, it also has several
clinically relevant interactions.1-3